|
Diabetic Nephropathy
|
0.300 |
GeneticVariation
|
disease |
LHGDN |
CTGF has emerged as a biological candidate gene for diabetic nephropathy; however, no significant association was detected between common CTGF SNPs and nephropathy in this population.
|
16501850 |
2006 |
|
Diabetic Nephropathy
|
0.300 |
GeneticVariation
|
disease |
BEFREE |
Resequencing of the characterised CTGF gene to identify novel or known variants, and analysis of their association with diabetic nephropathy.
|
16501850 |
2006 |
|
Diabetic Nephropathy
|
0.300 |
Biomarker
|
disease |
LHGDN |
In summary, CTGF inhibits matrix degradation by increasing TIMP-1 expression, and by this action it contributes to the inhibition of matrix breakdown by high glucose, implying that CTGF has a role in the reduced matrix degradation observed in diabetic nephropathy.
|
15345671 |
2004 |
|
Diabetic Nephropathy
|
0.300 |
Biomarker
|
disease |
LHGDN |
Plasma CTGF contributes significantly to prediction of ESRD and mortality in patients with type 1 diabetic nephropathy.
|
18344285 |
2008 |
|
Diabetic Nephropathy
|
0.300 |
Biomarker
|
disease |
BEFREE |
We have detected the expression of YAP, TEAD and CTGF in normal people (n=10) and patients with DN (n=51) by immunohistochemical and immunofluorescence staining and evaluated the relationship among clinical, pathologic data and YAP expression in type 2 diabetic nephropathy.
|
30720184 |
2019 |
|
Diabetic Nephropathy
|
0.300 |
Biomarker
|
disease |
BEFREE |
We aimed to identify microRNAs (miRNAs) targeting CTGF on podocytes in diabetic nephropathy.
|
26063197 |
2015 |
|
Diabetic Nephropathy
|
0.300 |
Biomarker
|
disease |
RGD |
XLF-III-43, a novel coumarin-aspirin compound, prevents diabetic nephropathy in rats via inhibiting advanced glycation end products.
|
19895808 |
2010 |
|
Diabetic Nephropathy
|
0.300 |
Biomarker
|
disease |
RGD |
Irbesartan ameliorates diabetic nephropathy by reducing the expression of connective tissue growth factor and alpha-smooth-muscle actin in the tubulointerstitium of diabetic rats.
|
19065061 |
2009 |
|
Diabetic Nephropathy
|
0.300 |
Biomarker
|
disease |
BEFREE |
However, there was no significant difference in the percentage of CTGF mRNA-positive cells between DN and IgA-N. Our study indicates that CTGF may play an important role in the development and progression of glomerulosclerosis in DN and IgA-N, which are both accompanied by mesangial matrix expansion and comprise two major causes of end-stage renal failure.
|
15012739 |
2003 |
|
Diabetic Nephropathy
|
0.300 |
Biomarker
|
disease |
BEFREE |
Urine CTGF may be a good marker for the prediction of diabetic nephropathy.
|
24192280 |
2013 |
|
Diabetic Nephropathy
|
0.300 |
Biomarker
|
disease |
BEFREE |
Treatment with the CTGF ASO for 8 wk reduced serum creatinine and attenuated urinary albuminuria and proteinuria in diabetic db/db mice, a model of type 2 DN.
|
17554073 |
2007 |
|
Diabetic Nephropathy
|
0.300 |
Biomarker
|
disease |
BEFREE |
Glomerular expression of thrombospondin-1, transforming growth factor beta and connective tissue growth factor at different stages of diabetic nephropathy and their interdependent roles in mesangial response to diabetic stimuli.
|
16270194 |
2005 |
|
Diabetic Nephropathy
|
0.300 |
Biomarker
|
disease |
BEFREE |
Elevated Urinary Connective Tissue Growth Factor in Diabetic Nephropathy Is Caused by Local Production and Tubular Dysfunction.
|
26171399 |
2015 |
|
Diabetic Nephropathy
|
0.300 |
Biomarker
|
disease |
BEFREE |
Mesangial cell hypertrophy is one of the earliest abnormalities of diabetic nephropathy; therefore, therapeutic strategies targeting CTGF may be beneficial in controlling DN.
|
12239232 |
2002 |
|
Diabetic Nephropathy
|
0.300 |
Biomarker
|
disease |
BEFREE |
Unraveling the role of connective tissue growth factor in diabetic nephropathy.
|
18235518 |
2008 |
|
Diabetic Nephropathy
|
0.300 |
Biomarker
|
disease |
BEFREE |
Excessive growth of glomerular mesangial cells and overexpression of transforming growth factor-beta1 (TGF-beta1) and connective tissue growth factor (CTGF) are the pathological features of diabetic nephropathy.
|
20460752 |
2010 |
|
Diabetic Nephropathy
|
0.300 |
Biomarker
|
disease |
BEFREE |
Long-term inhibition and targeting TGFbeta(1) directly is problematic, therefore, a more fruitful direction targeting diabetic nephropathy may involve the development of therapeutic strategies specifically targeting CTGF.
|
17300978 |
2008 |
|
Diabetic Nephropathy
|
0.300 |
Biomarker
|
disease |
LHGDN |
Therefore, the cooperation between CTGF and IGF-I might be involved in glucose-induced matrix accumulation in tubulointerstitial fibrosis and might contribute to the pathogenesis of diabetic nephropathy.
|
14633859 |
2003 |
|
Diabetic Nephropathy
|
0.300 |
Biomarker
|
disease |
BEFREE |
CTGF/CCN2 activates canonical Wnt signalling in mesangial cells through LRP6: implications for the pathogenesis of diabetic nephropathy.
|
21237163 |
2011 |
|
Diabetic Nephropathy
|
0.300 |
Biomarker
|
disease |
LHGDN |
In this cross-sectional study, the magnitude of urinary CTGF-N excretion was related to the severity of diabetic nephropathy.
|
12941731 |
2003 |
|
Diabetic Nephropathy
|
0.300 |
Biomarker
|
disease |
LHGDN |
U-CTGF in patients with diabetic nephropathy (n = 89, median 155 pmol/24 h [interquartile range 96-258]) was significantly higher than in microalbuminuric (n = 79, 100 [65-78]) and normoalbuminuric (n = 150, 85 [48-127]) patients and control subjects (n = 29, 100 [78-114]).
|
16373901 |
2006 |
|
Diabetic Nephropathy
|
0.300 |
Biomarker
|
disease |
BEFREE |
By determining the expression of transforming growth factor-β1 (TGF-β1), connective tissue growth factor (CTGF), collagen type IV (ColIV) and fibronectin (FN) levels in high glucose-cultured glomerular mesangial cells (MCs), the present study aimed to assess the anti-proliferative and anti-fibrotic effects of SIT on the therapeutic potential for the prevention of DN and its mechanism.
|
29042993 |
2017 |
|
Diabetic Nephropathy
|
0.300 |
AlteredExpression
|
disease |
BEFREE |
Hyperglycemia causes renal cell damage via CCN2-induced activation of the TrkA receptor: implications for diabetic nephropathy.
|
22586581 |
2012 |
|
Diabetic Nephropathy
|
0.300 |
AlteredExpression
|
disease |
BEFREE |
In this review, we only focus on the potential renoprotective therapeutic agents which can specifically abolish CCN2 expression or nonspecifically inhibit CCN2 expression for retarding the development and progression of DN.
|
26421309 |
2015 |
|
Diabetic Nephropathy
|
0.300 |
AlteredExpression
|
disease |
LHGDN |
THBS1, latent and active TGFB1, and CTGF, were detected by immunohistochemistry and in situ hybridisation in biopsies from 19 insulin-dependent diabetic patients with incipient, manifest and advanced diabetic nephropathy, and in 11 control kidneys.
|
16270194 |
2005 |